Cargando…

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells

Chimeric antigen receptor (CAR)-T cells have not made significant progress in the treatment of acute myeloid leukemia (AML) in earlyclinical studies. This lack of progress could be attributed in part to the immunosuppressive microenvironment of AML, such as monocyte-like myeloid-derived suppressor c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Xin, Xie, Danni, Sun, Rui, Lu, Wenyi, Xiao, Xia, Yu, Yibing, Meng, Juanxia, Zhao, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461507/ https://www.ncbi.nlm.nih.gov/pubmed/37645216 http://dx.doi.org/10.1080/2162402X.2023.2248826

Ejemplares similares

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

Downregulation of NKG2DLs by TGF-β in human lung cancer cells
por: Lee, Young Shin, et al.
Publicado: (2021)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2021)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

The TGF‐β‐induced up‐regulation of NKG2DLs requires AKT/GSK‐3β‐mediated stabilization of SP1
por: Chen, Xiao‐Hui, et al.
Publicado: (2017)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

An optimized filling method for capillary DLS
por: Ruseva, Valentina, et al.
Publicado: (2019)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity
por: Lynn, Rachel C, et al.
Publicado: (2016)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells
por: Cornet-Masana, Josep M., et al.
Publicado: (2019)

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
por: Richards, Rebecca M., et al.
Publicado: (2021)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors
por: Draghiciu, Oana, et al.
Publicado: (2011)

NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells
por: Ibáñez-Navarro, Marta, et al.
Publicado: (2023)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell
por: Sun, Yao, et al.
Publicado: (2019)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy
por: Wang, Jiaxi, et al.
Publicado: (2023)

Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention
por: Baragaño Raneros, Aroa, et al.
Publicado: (2014)

In vivo generated human CAR T cells eradicate tumor cells
por: Agarwal, Shiwani, et al.
Publicado: (2019)

Disengaging Leadership Scale (DLS): Evidence of Initial Validity
por: Nikolova, Irina, et al.
Publicado: (2021)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model
por: Wang, Dawei, et al.
Publicado: (2020)

piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
por: Du, Zhicheng, et al.
Publicado: (2021)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

The characterization of exosomes from fibrosarcoma cell and the useful usage of Dynamic Light Scattering (DLS) for their evaluation
por: Lyu, Tae Seong, et al.
Publicado: (2021)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro
por: Zarei, Mahdi, et al.
Publicado: (2023)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ln0ni267ev8r439t0jfthbge53